The Use of Prednisolone 2.5 mg Daily During Ramadan Fasting in Patients With Adrenal Insufficiency

ABSTRACT Background A previous study had established the safety and preserved of quality of life in patients with adrenal insufficiency (AI) who received prednisolone 5 mg once daily at sahur (predawn) during Ramadan fasting. It has been postulated that a lower dose of prednisolone between 2 and 3 m...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Clinical endocrinology (Oxford) 2025-02, Vol.102 (2), p.103-110
Hauptverfasser: Mok, Meng‐Loong, Farook, Nusrath Salma, Hee, Nicholas Ken Yoong, Sarvanandan, Tharsini, Lim, Quan‐ Hziung, Lim, Lee‐Ling, Vethakkan, Shireene, Ratnasingam, Jeyakantha
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:ABSTRACT Background A previous study had established the safety and preserved of quality of life in patients with adrenal insufficiency (AI) who received prednisolone 5 mg once daily at sahur (predawn) during Ramadan fasting. It has been postulated that a lower dose of prednisolone between 2 and 3 mg may be sufficient for glucocorticoid replacement in this group of patients. This study aimed to assess the safety and effect on quality of life in patients with AI given prednisolone 2.5 mg during Ramadan fasting. Methods Patients with AI on twice‐daily hydrocortisone, who had low or moderate risk of adrenal crisis and intended to fast, were recruited. Patients were given prednisolone 2.5 mg once daily taken at sahur(predawn) and Ramadan education was given. Weight, sleep duration, physical activity, biochemical parameters and quality of life measurements (SF‐36 questionnaire) were analysed at the end of Ramadan and compared against the patient's own baseline readings before the start of Ramadan. Results A total of 16 patients (10 men, median age 60 [50.3, 68] years) were recruited. All patients were on 15–20 mg of hydrocortisone (in divided doses) before Ramadan, and intended to fast. Five of the participants had type 2 diabetes with low IDF‐DAR risk category. 18.7% of the participants were unable to complete all 29 days of fasting. Up to 62.5% of the participants reported at least one adverse event. There was a statistically significant reduction in weight (median: −1.6 [−2.5, −0.3] kg, p 
ISSN:0300-0664
1365-2265
1365-2265
DOI:10.1111/cen.15176